The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function.

The present study will explore the potential clinical advantages of the above described innovative treatment concept as a rechallenge treatment: following the disease progression during initiated first-line ICI-therapy, or following discontinuation of ICI-therapy, a same previously used agent (ICI) will be added the PTI to boost its immunologic anti-tumor effects. The treatment response will be measured by comparing the progression-free survival 1 (PFS-1) (ICI-therapy alone) and progression-free survival 2 (PFS-2) (combined rechallange PTI-ICI) rates.

The primary endpoint will be ∆PFS rate (PFS-2 vs PFS-1) assessed according to the modified iRECIST criteria. Secondary endpoints will include overall survival, toxicity, and exploration and validation of the anti-cancer immunity.

Once treatment is completed, follow up will be performed on a regular basis (at 6 and 12 weeks, and every 3 months later on) by CT, MRT or PET-CT imaging to allow for endpoints assessment, or at any time in case of suspected disease progression. Patients will also be followed clinically with history and physical examinations, vital signs, and laboratory examinations as indicated.

The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. The present novel, combined approach will be offered as an alternative to a palliative or best supportive care. In previous studies PTI has shown to be effective, safe and capable of inducing significant immunomodulatory and neoadjuvant effects in complex unresectable resistant bulky tumors, lung cancer including. PTI was previously explored alone, therefore so far never combined with any kind of systemic therapy, in order first to assess its own efficiency when immunomodulation and tumor control is concerned. Its combination with immunotherapy is very attractive due to its high immunostimulative potential as shown in previous studies. Aditionally, it has been shown that the PD-L1 level is widely upregulated after radiotherapy, on not only tumor cells, but also macrophages, myeloid-derived suppressor cells, and derived exosomes, which correlate to improved effectiveness of immunotherapy resulting in better therapeutic outcomes. Taking all together into account, it is expected from the PTI-ICI combination to generate more powerful immunomodulatory anti-tumor effect compared to the conventional radiotherapy combination with immunotherapy leading to improved tumor control and prognosis. One of the reasons for this is the PTI´s sparring effect of PIM, which otherwise is irradiated with a full dose of radiation when conventional radiotherapy is used and therefore destroyed, which is why the same conventional radiotherapy is quite immunosuppressive and is not expected to work optimally when combined with immunotherapy. In order to improve the radiotherapy therapeutic ratio by the highly complex unresectable tumors left without other therapeutic options, PTI was purposefully designed to add to the radiation-mediated tumor cell killing component, an additional component of radiation-induced immune-mediated tumor cell killing, a concept known as the "radiation-vaccine". This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function. PTI is going to be delivered as a single fraction (1 day) in order to release the tumor antigens and pro-inflammatory cytokines from destroyed tumor cells which could then sensitize loco-regional (previously spared) immune cells surrounding the tumor, resulting in an immune anti-tumor response, like a true vaccine.

For the purpose of PTI-treatment planning, the targeted central tumor segment, or so-called BTV (Bystander Tumor Volume), will be delineated using the combination of 18F-FDG-PET-CT (PET-CT; not mandatory, if performed by patient for the purpose of the staging) and contrast-enhanced CT (mandatory). In case there is no PET-CT available at time of treatment planning the BTV will simply be contoured as the Gross Tumor Volume (GTV) minus 5-10mm. This margin will depend on the proximity of the nearby organs at risk (OAR) (excluding main bronchus or heart). PTI will be delivered with photons by means of stereotactic body radiotherapy (SBRT) technique. Based on tumor location, its volume and risk factors related to nearby critical structures, radiation dose might be reduced to 15Gy/fraction, according to patient´s individual risk factors, respectively. Regarding the ICI, an anti-PD-L1 antibody will be administered at three-week intervals until progression.

The present study will explore the potential clinical advantages of the above described innovative treatment concept as a rechallenge treatment: following the disease progression during initiated first-line ICI-therapy, or following discontinuation of ICI-therapy, a same previously used agent (ICI) will be added the PTI to boost its immunologic anti-tumor effects. The treatment response will be measured by comparing the progression-free survival 1 (PFS-1) (ICI-therapy alone) and progression-free survival 2 (PFS-2) (combined rechallange PTI-ICI) rates.

The analysis of the bio-molecular mechanisms potentially responsible for the observed clinical effects of the PTI-ICI treatment in terms of radiation-induced anti-tumor immune response will also be performed. This will include the anti-tumor immunity as profiling of peripheral blood mononuclear cells (PBMC) following the PTI-ICI therapy through translational immune studies on blood specimens. Two key cytokines that are involved in modulation of immune response, Interleukin-2 (IL-2) and Interferon Gamma (INFg), will serially be assessed, at baseline, after radiotherapy treatment, before each administration of the ICI in order to determine their potential role in immunomodulation by PTI-ICI.

This is a pilot study in which the investigators will enroll up to 10 patients with locally advanced or metastatic unresectable lung adenocarcinoma to assess the feasibility and potential effectiveness of a novel approach.

The hypothesis implies that for an effective immune modulation leading to improved therapeutic ratio, the entire tumor volume may not need to be irradiated but only a partial tumor volume sparing the PIM, in order to overcome the tumor tolerance initiating the immune cycle in radiation-spared PIM, resulting in tumoricidal radio-immune anti-tumor effects.

The primary endpoint will be ∆PFS rate (PFS-2 vs PFS-1) assessed according to the modified iRECIST criteria. Secondary endpoints will include overall survival, toxicity, and exploration and validation of the anti-cancer immunity.

Once treatment is completed, follow up will be performed on a regular basis (at 6 and 12 weeks, and every 3 months later on) by CT, MRT or PET-CT imaging to allow for endpoints assessment, or at any time in case of suspected disease progression. Patients will also be followed clinically with history and physical examinations, vital signs, and laboratory examinations as indicated.

Inclusion Criteria:

1. Written informed consent
2. Biopsy proven unresectable lung adenocarcinoma
3. Ineligibility for surgery and conventional curative (whole tumor) radiotherapy, and relapsed/refractory to any previous standard of care therapy including ICI
4. Age ≥ 18 years,
5. Female patients must either be of non-reproductive potential (i.e. post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) OR women of fertile age must have adequate conception prevention measures and must have a negative serum pregnancy test upon study entry,
6. Patient is willing and able to comply with the follow up including scheduled visits and examinations,
7. Adequate immune blood profile (not being immunodepressed): Leucocyte count ≥4000, Neutrophils count ≥1000.
8. PDL-1 ≥ 1%

Exclusion Criteria:

1. Patients with resectable/curable lung cancer
2. Tumors suitable for the standard of care therapies including surgery or conventional curative (whole tumor) radio-chemotherapy
3. Lung cancer histology other than adenocarcinoma
4. Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
5. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, (1)
6. Patients with uncontrolled seizures.
7. Inadequate immune blood profile (being potentially immunodepressed): Leucocyte count <4000, Neutrophils count <1000.
8. PDL-1 < 1%

Demographics, Patient- and Tumor-features